Handelsbanken Fonder’s Inovio Pharmaceuticals INO Stock Holding History

Handelsbanken Fonder’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,083	Closed	-$133K	–	1652
2022 Q1	$133K	Hold	3,083	–	–	﹤0.01%	1674
2021 Q4	$185K	Hold	3,083	–	–	﹤0.01%	1718
2021 Q3	$265K	Hold	3,083	–	–	﹤0.01%	1613
2021 Q2	$343K	Buy	3,083 +375	+14%	+$36K	﹤0.01%	1585
2021 Q1	$302K	Hold	2,708	–	–	﹤0.01%	1445
2020 Q4	$288K	Buy	+2,708	New	+$361K	﹤0.01%	1421

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Handelsbanken Fonder's INO Position: Q2 2022 in Review

Handelsbanken Fonder sold out of Inovio Pharmaceuticals (INO) in Q2 2022, closing a stake of 3,083 shares — an estimated $133K sold.

Handelsbanken Fonder first reported a position in INO in Q4 2020 and held it in 6 quarters. The position peaked at $343K in Q2 2021. 184 funds tracked by Wall St. Rank hold INO as of Q2 2022.

Handelsbanken Fonder reported no remaining Inovio Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Handelsbanken Fonder sold 3,083 Inovio Pharmaceuticals shares in Q2 2022, an estimated $133K.
Handelsbanken Fonder first reported a position in Inovio Pharmaceuticals in Q4 2020 and held it in 6 quarters.
Handelsbanken Fonder's Inovio Pharmaceuticals position peaked at $343K in Q2 2021.
184 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2022.

Based on Handelsbanken Fonder's 13F filing for Q2 2022, filed 3 Aug 2022.